Breaking News

You are here » Indian-Commodity  :  Corporate  :  AstraZeneca Pharma receives Marketing Authorization from DCGI

18-Oct2017

AstraZeneca Pharma receives Marketing Authorization from DCGI

AstraZeneca Pharma India has received Import and Market Permission in Form 45 (Marketing Authorization) from the Drug Controller General of India (DCGI) for FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR).

The FDC of Dapagliflozin + Metformin Hydrochloride (Extended Release) film coated tablets (XIGDUO XR) is indicated as an ajunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.



Related News

View all news

NCLT levies penalty on Tata Chemicals

The National Company Law Tribunal (NCLT) Mumbai, has levied a penalty of Rs 10 lakh on Tata Chemicals for filing a petition fraudulently and with malicious intent to liquidate Raj Process Equipment and......

Reliance Industries' arms to launch new e-commerce platform

Reliance Industries' group companies--Reliance Jio and Retail will launch a new e-commerce platform in the country. This project will empower 12 lakh small retailers in Gujarat.Reliance Industries is India's......

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......